Subserous invasion of VEGF‑C‑producing cancer cells is a possible risk factor for ileal ulceration in the non‑metastatic mucosal layer during bevacizumab‑combined chemotherapy for recurrent ovarian cancer: A case report

Matsumoto,Takeo; Mizumoto,Yasunari; Nakade,Kyohei; Obata,Takeshi; Matsuoka,Ayumi; Myojo,Subaru; Ono,Masanori; Nakamura,Mitsuhiro; Fujiwara,Hiroshi

doi:10.3892/mco.2017.1403

November-2017 Volume 7 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2017 Volume 7 Issue 5

Full Size Image

Case Report Open Access

Subserous invasion of VEGF‑C‑producing cancer cells is a possible risk factor for ileal ulceration in the non‑metastatic mucosal layer during bevacizumab‑combined chemotherapy for recurrent ovarian cancer: A case report

Authors:
- Takeo Matsumoto
- Yasunari Mizumoto
- Kyohei Nakade
- Takeshi Obata
- Ayumi Matsuoka
- Subaru Myojo
- Masanori Ono
- Mitsuhiro Nakamura
- Hiroshi Fujiwara
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa 920‑8641, Japan

Copyright: © Matsumoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 820-824
|
Published online on: September 1, 2017

https://doi.org/10.3892/mco.2017.1403
Expand metrics +

Abstract

A 65‑year‑old woman received chemotherapy using paclitaxel and carboplatin following optimal debulking surgery for ovarian cancer stage IV. Five months later, intra‑abdominal recurrence was diagnosed, and second‑line chemotherapy using nogitecan and bevacizumab was administered. After five courses, the patient presented with a symptom of subileus and subsequent intestinal perforation occurred. An emergent surgery revealed two perforation sites and longitudinally extended ulcerative lesions in the ileum. Pathologically, although metastatic sites were not observed in the submucus layer just beneath the ulcers, there were a number of vascular endothelial growth factor (VEGF)‑C‑positive cancer cell invasion sites along with marked edema and an increase of the lymphatic endothelial cell marker ‘podoplanin’‑positive cells in subserous regions. Since bevacizumab is able to inhibit VEGF‑A, but not VEGF‑C, and induce compensatory increase in VEGF‑C production, these findings suggest that the local disturbance of lymphatic circulation in the subserous regions by VEGF‑C‑producing cancer cells is a possible risk factor for the development of intestinal ulceration and perforation during bevacizumab therapy.

View Figures

View References

1	Reinthaller A: Antiangiogenic therapies in ovarian cancer. Memo. 9:139–143. 2016. View Article : Google Scholar : PubMed/NCBI
2	Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014. View Article : Google Scholar : PubMed/NCBI
3	Husain A, Wang Y, Hanker LC, Ojeda B, Anttila M, Breda E, Vuylsteke P and Pujade-Lauraine E: Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer. Gynecol Oncol. 142:465–470. 2016. View Article : Google Scholar : PubMed/NCBI
4	Martin JY, Urban RR, Liao JB and Goff BA: Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. J Gynecol Oncol. 27:e472016. View Article : Google Scholar : PubMed/NCBI
5	Keating GM: Bevacizumab: A review of its use in advanced cancer. Drugs. 74:1891–1925. 2014. View Article : Google Scholar : PubMed/NCBI
6	Grau S, Thorsteinsdottir J, von Baumgarten L, Winkler F, Tonn JC and Schichor C: Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. J Neurooncol. 104:103–112. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ogata K, Takamori H, Umezaki N, Yagi T, Ogawa K, Ozaki N, Hayashi H, Tanaka H, Ikuta Y and Doi K: Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer. J Chemother. 20:1–3. 2016.
8	Miller MJ, McDole JR and Newberry RD: Microanatomy of the intestinal lymphatic system. Ann N Y Acad Sci. 1207 Suppl 1:E21–E28. 2010. View Article : Google Scholar : PubMed/NCBI
9	Unthank JL and Bohlen HG: Lymphatic pathways and role of valves in lymph propulsion from small intestine. Am J Physiol. 254:G389–G398. 1988.PubMed/NCBI
10	von der Weid PY, Rehal S and Ferraz JG: Role of the lymphatic system in the pathogenesis of Crohn's disease. Curr Opin Gastroenterol. 27:335–341. 2011. View Article : Google Scholar : PubMed/NCBI
11	Kalima TV, Saloniemi H and Rahko T: Experimental regional enteritis in pigs. Scand J Gastroenterol. 11:353–362. 1976.PubMed/NCBI
12	Pedica F, Ligorio C, Tonelli P, Bartolini S and Baccarini P: Lymphangiogenesis in Crohn's disease: An immunohistochemical study using monoclonal antibody D2-40. Virchows Arch. 452:57–63. 2008. View Article : Google Scholar : PubMed/NCBI
13	Holzheimer RG and Mannick JA: Surgical Treatment: Evidence-Based and Problem-Oriented. Part II: Small bowel obstruction. WZuckschwerdt Verlag GmbH. Munich: 2001
14	Goldman J, Rutkowski JM, Shields JD, Pasquier MC, Cui Y, Schmökel HG, Willey S, Hicklin DJ, Pytowski B and Swartz MA: Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J. 21:1003–1012. 2007. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Subserous invasion of VEGF‑C‑producing cancer cells is a possible risk factor for ileal ulceration in the non‑metastatic mucosal layer during bevacizumab‑combined chemotherapy for recurrent ovarian cancer: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles